News

Medipak Group chairman Dr Khalid J Chowdhry was quoted by the Associated Press of Pakistan (APP) as saying that the company produces nearly 150 million units of the

Following the receipt of approval from the Investigational Review Board, the study is expected to enroll patients in the summer of 2013. University of Texas M.D. Anderson Cancer

Weight-Loss Fat Burner Patch is designed to reduce the fat content drastically in the body and to reduce the fat deposition. The fat burner patch crossed its research

The oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases completed Phase I studies and is ready to enter Phase IIb studies. Scynexis president

Formulated in cherry and grape flavors, RapiMed dissolvable pain relief remedy 80mg and 160mg tablets will be manufactured and distributed by CPI within the US and North America.

Researchers from UCSF will be able to access Pfizer’s small-molecule drug development capabilities, and will collectively work with the latter’s scientists to develop drug candidates that can bring

A pending patent application covering amorphous rifaximin, an issued patent covering the product along with related intellectual property rights that was acquired by Olon from Apotex Pharmachem were

Conducted on 447 patients with previously untreated CLL and evaluated by an independent review committee (IRC), the study met its primary endpoint of progression free survival (PFS). Patients

With the acquisition of 500,000ft² commercial manufacturing facility, UPM expects to expand capacity for production of solid oral dosage tablets and capsules, in addition to semi-solid creams and